GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome

[1]  Julie Brown,et al.  Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. , 2016, The Cochrane database of systematic reviews.

[2]  W. Martins,et al.  Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[3]  Keren Amichay,et al.  GnRH-antagonist programming versus GnRH agonist protocol: a randomized trial. , 2015, European journal of obstetrics, gynecology, and reproductive biology.

[4]  B. Tarlatzis,et al.  Serum vascular endothelial growth factor levels following luteal gonadotrophin‐releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome , 2014, BJOG : an international journal of obstetrics and gynaecology.

[5]  P. Devroey,et al.  Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. , 2014, Fertility and sterility.

[6]  B. Sancak,et al.  A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. , 2014, European journal of obstetrics, gynecology, and reproductive biology.

[7]  W. Martins,et al.  Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. , 2014, Fertility and sterility.

[8]  R. Orvieto.  Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma , 2013, Journal of Ovarian Research.

[9]  B. Tan,et al.  Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee , 2013, Human fertility.

[10]  B. Tan,et al.  Management of Ovarian Hyperstimulation Syndrome Guidelines. Produced on behalf of the BFS Policy and Practice Committee , 2013, Human fertility.

[11]  P. Humaidan,et al.  GnRH agonist triggering: recent developments. , 2013, Reproductive biomedicine online.

[12]  P. Patrizio,et al.  GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate. , 2013, Reproductive biomedicine online.

[13]  S. Palomba,et al.  Pronuclear morphology evaluation in in vitro fertilization (IVF) / intracytoplasmic sperm injection (ICSI) cycles: a retrospective clinical review , 2013, Journal of Ovarian Research.

[14]  D. Ezcurra,et al.  Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment , 2012, Reproductive Biology and Endocrinology.

[15]  J. García-Velasco.  Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. , 2012, Fertility and sterility.

[16]  S. Zhai,et al.  Cabergoline for preventing ovarian hyperstimulation syndrome. , 2012, The Cochrane database of systematic reviews.

[17]  P. Claman,et al.  The diagnosis and management of ovarian hyperstimulation syndrome. , 2011, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[18]  P. Devroey,et al.  An OHSS-Free Clinic by segmentation of IVF treatment. , 2011, Human reproduction.

[19]  A. Abou-Setta,et al.  Gonadotrophin-releasing hormone antagonists for assisted reproductive technology in women with poor ovarian response. subgroup analysis of cochrane systematic review and meta-analysis , 2011 .

[20]  A. Pellicer,et al.  Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. , 2011, Fertility and sterility.

[21]  G. Griesinger,et al.  Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. , 2011, Fertility and sterility.

[22]  P. Bossuyt,et al.  Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. , 2007, Human reproduction.

[23]  J. Lessing,et al.  [Ovarian hyperstimulation syndrome]. , 1995, Harefuah.

[24]  N. Amso,et al.  Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. , 2017, The Cochrane database of systematic reviews.

[25]  S. Sunkara,et al.  Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. , 2014, Human reproduction update.

[26]  P. Talwar,et al.  VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status. , 2014, Medical journal, Armed Forces India.

[27]  Mature Oocyte.  Mature oocyte cryopreservation: a guideline The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted , 2012 .

[28]  V. Senikas,et al.  JOINT SOGC-CFAS CLINICAL PRACTICE GUIDELINE The diagnosis and management of ovarian hyperstimulation syndrome ☆ , 2012 .

[29]  F. Broekmans,et al.  AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. , 2011, Human reproduction update.

[30]  M. Gysler,et al.  JOINT SOGC-CFAS CLINICAL PRACTICE GUIDELINE , 2010 .